DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

Phase 2

Recruiting

Conditions: Myeloid Malignancies

Interventions: Drug: Olutasidenib

First Posted Date: 2024-10-31

Last Posted Date: 2025-04-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT06668584

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

Phase 1

Recruiting

Conditions: AML

Interventions: Drug: MBG-453 + Azacitidine

First Posted Date: 2024-10-30

Last Posted Date: 2025-04-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT06664879

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Phase 1

Recruiting

Conditions: Phase 1
Recurrent Melanoma
Refractory Melanoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-10-28

Last Posted Date: 2025-05-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT06660420

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Symptom Burden and Health Related Quality of Life of Cancer Patients With Concurrent Heart Failure

Recruiting

Conditions: Heart Failure

First Posted Date: 2024-10-24

Last Posted Date: 2025-01-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT06656715

Locations: 🇺🇸
The University of Texas of MD Anderson Cancer Center, Houston, Texas, United States

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

Recruiting

Conditions: Chronic Pancreatitis
Exocrine Pancreas Carcinoma
Recurrent Acute Pancreatitis

First Posted Date: 2024-10-21

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1600

Registration Number: NCT06651580

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

and more 23 locations

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Phase 2

Not yet recruiting

Conditions: Solid Tumors

Interventions: Drug: SAR444881
Drug: Cemiplimab

First Posted Date: 2024-10-21

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06651593

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active

Phase 2

Recruiting

Conditions: Brain Metastases

First Posted Date: 2024-10-18

Last Posted Date: 2025-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 316

Registration Number: NCT06649058

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Recruiting

Conditions: Arthritis
Polymyalgia Rheumatica
Immune Checkpoint Inhibitors

First Posted Date: 2024-10-17

Last Posted Date: 2025-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06647134

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study

Phase 1

Recruiting

Conditions: Impulse Control Disorder

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06639594

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Not Applicable

Recruiting

Conditions: Cytomegalovirus Cell Mediated Immunity
Hematopoietic Cell Transplant

Interventions: Procedure: Hematopoietic Cell Transplant
Drug: Letermovir

First Posted Date: 2024-10-15

Last Posted Date: 2025-05-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 105

Registration Number: NCT06639854

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy